Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone.
Intermittent exogenous parathyroid hormone (PTH) is a potent osteoanabolic agent used for the treatment of severe osteoporosis. Two molecules of recombinant PTH are commercially available: the full-length PTH (PTH 1-84) and teriparatide (PTH 1-34). We present the first report of PTH-induced mild, asymptomatic, normochromic normocytic anemia in a postmenopausal woman treated sequentially with PTH 1-84 and PTH 1-34. Anemia was more pronounced with PTH 1-84 compared to PTH 1-34 and was reversed with each regimen discontinuation. We suggest monitoring of hematocrit and hemoglobin in PTH-treated patients, especially when PTH 1-84 is used.
Anastasilakis
Athanasios D
AD
Department of Endocrinology, 424 Military Hospital, Thessaloniki, Greece. anastath@endo.gr
Savvides
Mattheos
M
Polyzos
Stergios A
SA
Georgopoulos
Christos
C
Delaroudis
Sideris
S
D000740:Anemia / Q000139:chemically induced* / Q000150:complications; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications* / Q000188:drug therapy; D010281:Parathyroid Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D019379:Teriparatide / Q000009:adverse effects* / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D011994:Recombinant Proteins; D019379:Teriparatide